Deep Vein Thrombosis (DVT)

Also known as: DVT / Deep Vein Thrombosis / Deep-Vein Thrombosis / DVT - Deep Vein Thrombosis / Deep venous thrombosis NOS / DVT - not obstetric / Thrombosis venous deep / Deep vein thrombosis NOS

DrugDrug NameDrug Description
DB06605ApixabanApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
DB06779DalteparinDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DB11095DesirudinDesirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.
DB09075EdoxabanEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
DB01225EnoxaparinEnoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin's inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DB00569FondaparinuxFondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
DB08813NadroparinNadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DB06228RivaroxabanRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
DB06822TinzaparinTinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DrugDrug NameTargetType
DB06605ApixabanCoagulation factor Xtarget
DB06605ApixabanCytochrome P450 3A4enzyme
DB06605ApixabanCytochrome P450 1A2enzyme
DB06605ApixabanCytochrome P450 2C8enzyme
DB06605ApixabanCytochrome P450 2C9enzyme
DB06605ApixabanCytochrome P450 2C19enzyme
DB06605ApixabanCytochrome P450 2J2enzyme
DB06605ApixabanMultidrug resistance protein 1transporter
DB06605ApixabanATP-binding cassette sub-family G member 2transporter
DB06605ApixabanCytochrome P450 3A5enzyme
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB11095DesirudinCarboxypeptidase A1enzyme
DB09075EdoxabanCoagulation factor Xtarget
DB09075EdoxabanMultidrug resistance protein 1transporter
DB01225EnoxaparinCoagulation factor Xtarget
DB00569FondaparinuxCoagulation factor Xtarget
DB08813NadroparinProto-oncogene c-Fostarget
DB08813NadroparinMyc proto-oncogene proteintarget
DB06228RivaroxabanCoagulation factor Xtarget
DB06228RivaroxabanCytochrome P450 3A4enzyme
DB06228RivaroxabanCytochrome P450 2J2enzyme
DB06228RivaroxabanMultidrug resistance protein 1transporter
DB06228RivaroxabanCytochrome P450 3A5enzyme
DB06228RivaroxabanATP-binding cassette sub-family G member 2transporter
DB06822TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
DB06822TinzaparinIntegrin alpha-4target
DB06822TinzaparinStromal cell-derived factor 1target
DrugDrug NamePhaseStatusCount
DB00569Fondaparinux2 / 3Unknown Status1
DB11728Fondaparinux2 / 3Unknown Status1
DB01109Heparin2 / 3Completed1
DB01109Heparin2 / 3Unknown Status1
DB08813Nadroparin2 / 3Unknown Status1
DB06822Tinzaparin2 / 3Completed1
DB06605Apixaban3Active Not Recruiting1
DB06695Dabigatran etexilate3Recruiting1
DB06779Dalteparin3Active Not Recruiting1
DB06228Rivaroxaban3Active Not Recruiting1
DB00945Acetylsalicylic acid4Withdrawn1
DB11121Chloroxylenol4Not Yet Recruiting1
DB06695Dabigatran etexilate4Recruiting1
DB08995Diosmin4Active Not Recruiting1
DB06228Rivaroxaban4Active Not Recruiting1
DB00302Tranexamic acid4Not Yet Recruiting1
DB06605ApixabanNot AvailableCompleted1
DB06605ApixabanNot AvailableRecruiting1
DB09258BemiparinNot AvailableCompleted1
DB00115CyanocobalaminNot AvailableCompleted1
DB06695Dabigatran etexilateNot AvailableRecruiting1
DB06779DalteparinNot AvailableRecruiting1
DB09075EdoxabanNot AvailableRecruiting1
DB01225EnoxaparinNot AvailableCompleted1
DB01225EnoxaparinNot AvailableRecruiting2
DB11728FondaparinuxNot AvailableCompleted1
DB00569FondaparinuxNot AvailableRecruiting1
DB11728FondaparinuxNot AvailableRecruiting1
DB11728FondaparinuxNot AvailableUnknown Status1
DB01109HeparinNot AvailableCompleted1
DB06228RivaroxabanNot AvailableCompleted1
DB06228RivaroxabanNot AvailableRecruiting1
DB01098RosuvastatinNot AvailableCompleted1
DB06822TinzaparinNot AvailableCompleted1
DB00682WarfarinNot AvailableCompleted1
DB00682WarfarinNot AvailableRecruiting1